Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis

Table 1

Trial design features and results.

Author/year	Trial/program	Interventions		Trial duration (weeks)	Experimental		Control
		Experimental	Control		Number of events		Number of events
Gallwitz et al. 2012 [11]	EUREXA	Exenatide	Glimepiride	102	3	515	1	514
Russel-Jones et al. 2012 [12]	DURATION-4	Exenatide	Metformin	26	0	248	1	246
Kadowaki et al. 2010 [13]		Exenatide	Placebo	24	1	144	0	35
Xu et al. 2014 [14]	CONFIDENCE	Exenatide	Premixed insulin	48	1	110	0	114
Jaiswal et al. 2015 [15]		Exenatide	Glargine	77	1	22	0	24
Diamant et al. 2014 [16]	DURATION-3	Exenatide	Glargine	156	3	140	2	147
Diamant et al. 2012 [17]		Exenatide	Glargine	84	2	173	1	173
Bergenstal et al. 2010 [18]	DURATION-2	Exenatide	Sitagliptin	26	0	160	1	166
Holman et al. 2017 [19]	EXSCEL	Exenatide	Placebo	167	355	7356	361	7396
Gadde et al. 2017 [20]	DURATION-NEO-2	Exenatide	Placebo	28	0	181	0	61
Weinstock et al. 2015 [21]	AWARD-5	Dulaglutide	Sitagliptin	26	8	606	5	315
Araki et al. 2015 [22]		Dulaglutide	Glargine	26	0	181	0	180
Blonde et al. 2015 [23]	AWARD-4	Dulaglutide	Glargine	52	0	588	0	296
Umpierrez et al. 2014 [24]	AWARD-3	Dulaglutide	Metformin	52	0	539	0	268
Pozzilli et al. 2017 [25]	AWARD-9	Dulaglutide	Glargine	28	0	150	1	150
Miyagawa et al. 2015 [26]		Dulaglutide	Placebo	52	0	281	0	70
		Liraglutide			1	141
Bailey et al. 2016 [27]	LIRA-SWITCH	Liraglutide	Sitagliptin	26	0	202	2	204
Zang et al. 2016 [28]		Liraglutide	Sitagliptin	26	0	183	2	184
Marso et al. 2016 (Liraglutide) [1]	LEADER	Liraglutide	Placebo	198	296	4668	279	4672
Pratley et al. 2011 [29]		Liraglutide	Sitagliptin	52	4	446	1	219
le et al. 2017 [30]	SCALE	Liraglutide	Placebo	160	11	1501	1	747
Marso et al. 2016 (Semaglutide) [31]	SUSTAIN-6	Semaglutide	Placebo	104	1	1648	4	1649
Ahrén et al. 2017 [32]	SUSTAIN 2	Semaglutide	Sitagliptin	52	2	818	2	407
Sorli et al. 2017 [33]	SUSTAIN 1	Semaglutide	Placebo	30	4	258	0	129
Davies et al. 2017 [34]		Semaglutide	Placebo	26	1	419	0	71
Aroda et al. 2017 [35]	SUSTAIN 4	Semaglutide	Glargine	30	4	722	1	360
Reusch et al. 2014 [36]	HARMONY 1	Albiglutide	Placebo	52	0	150	0	151
Home et al. 2015 [37]	HARMONY 5	Albiglutide	Placebo	156	0	271	1	115
Weissman et al. 2014 [38]	HARMONY 4	Albiglutide	Glargine	52	0	504	0	241
Nauck et al. 2015 [39]	HARMONY 2	Albiglutide	Placebo	52	2	204	0	105
Leiter et al. 2014 [40]		Albiglutide	Sitagliptin	52	0	249	0	246
Leiter et al. 2017 [41]		Albiglutide	Lispro	52	1	285	0	281
Yu et al. 2014 [42]	GetGoal-M-Asia	Lixisenatide	Placebo	24	0	196	0	194
Pfeffer et al. 2015 [43]	ELIXA	Lixisenatide	Placebo	108	72	3031	61	3032